For a number of years, coenzyme Q10 (CoQ10) was known for its key role in mitochondrial bioenergetics; later studies demonstrated its presence in other subcellular fractions and in blood plasma, and extensively investigated its antioxidant role. These 2 functions constitute the basis for supporting the clinical use of CoQ10. Also, at the inner mitochondrial membrane level, CoQ10 is recognized as an obligatory cofactor for the function of uncoupling proteins and a modulator of the mitochondrial transition pore. Furthermore, recent data indicate that CoQ10 affects the expression of genes involved in human cell signaling, metabolism and transport, and some of the effects of CoQ10 supplementation may be due to this property. CoQ10 deficiencies are due to autosomal recessive mutations, mitochondrial diseases, aging-related oxidative stress and carcinogenesis processes, and also statin treatment. Many neurodegenerative disorders, diabetes, cancer, and muscular and cardiovascular diseases have been associated with low CoQ10 levels as well as different ataxias and encephalomyopathies. CoQ10 treatment does not cause serious adverse effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. Oral administration of CoQ10 is a frequent antioxidant strategy in many diseases that may provide a significant symptomatic benefit.

1.
Adarsh K, Kaur H, Mohan V: Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors 32:145-149 (2008).
2.
Artuch R, Brea-Calvo G, Briones P, Aracil A, Galván M, et al: Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci 246:153-158 (2006).
3.
Beal MF: Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors 9:261-266 (1999).
4.
Belardinelli R, Muçaj A, Lacalaprice F, Solenghi M, Seddaiu G, et al: Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 27:2675-2681 (2006).
5.
Bentinger M, Tekle M, Dallner G: Coenzyme Q -biosynthesis and functions. Biochem Biophys Res Commun 396:74-79 (2010).
6.
Berbel-Garcia A, Barbera-Farre JR, Etessam JP, Salio AM, Cabello A, et al: Coenzyme Q10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 27:187-191 (2004).
7.
Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 40:445-453 (2006).
8.
Bonakdar RA, Guarneri E: Coenzyme Q10. Am Fam Physician 72:1065-1070 (2005).
9.
Brea-Calvo G, Rodríguez-Hernández A, Fernández-Ayala DJ, Navas P, Sánchez-Alcázar JA: Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines. Free Radic Biol Med 40:1293-1302 (2006).
10.
Bresolin N, Doriguzzi C, Ponzetto C, Angelini C, Moroni I, et al: Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 100:70-78 (1990).
11.
Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99:1409-1412 (2007).
12.
Celik T, Iyisoy A: Coenzyme Q10 and coronary artery bypass surgery: what we have learned from clinical trials. J Cardiothorac Vasc Anesth 23:935-936 (2009).
13.
Cooper JM, Schapira AH: Friedreich's ataxia: coenzyme Q10 and vitamin E therapy. Mitochondrion 7 Suppl:S127-135 (2007).
14.
Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH: Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol 15:1371-1379 (2008).
15.
Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, et al: Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 4:141ra190 (2012).
16.
Cordero MD, De Miguel M, Moreno Fernández AM, Carmona López IM, Garrido Maraver J, et al: Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 12:R17 (2010).
17.
Cordero MD, Alcocer-Gómez E, de Miguel M, Cano-García FJ, Luque CM, et al: Coenzyme Q10: a novel therapeutic approach for Fibromyalgia? Case series with 5 patients. Mitochondrion 11:623-625 (2011).
18.
Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA: Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q10 effect on clinical improvement. PLoS One 7:e35677 (2012).
19.
Cotán D, Cordero MD, Garrido-Maraver J, Oropesa-Ávila M, Rodríguez-Hernández A, et al: Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J 25:2669-2687 (2011).
20.
Crane FL: Biochemical functions of coenzyme Q10. J Am Coll Nutr 20:591-598 (2001).
21.
Chen RS, Huang CC, Chu NS: Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 37:212-218 (1997).
22.
De la Mata M, Garrido-Maraver J, Cotán D, Cordero MD, Oropesa-Avila M, et al: Recovery of MERRF fibroblasts and cybrids pathophysiology by Coenzyme Q10. Neurotherapeutics 9:446-463 (2012).
23.
Di Giovanni S, Mirabella M, Spinazzola A, Crociani P, Silvestri G, et al: Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 57:515-518 (2001).
24.
DiMauro S, Quinzii CM, Hirano M: Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest 117:587-589 (2007).
25.
Domae N, Sawada H, Matsuyama E, Konishi T, Uchino H: Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. Cancer Treat Rep 65:79-91 (1981).
26.
Emmanuele V, López LC, Berardo A, Naini A, Tadesse S, et al: Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol 69:978-983 (2012).
27.
Folkers K, Littarru GP, Ho L, Runge TM, Havanonda S, Cooley D: Evidence for a deficiency of coenzyme Q10 in human heart disease. Int Z Vitaminforsch 40:380-390 (1970).
28.
Folkers K, Vadhanavikit S, Mortensen SA: Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 82:901-904 (1985a).
29.
Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S: Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci USA 82:4513-4516 (1985b).
30.
Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, et al: Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69:836-841 (2012).
31.
Garrido-Maraver J, Cordero MD, Moñino ID, Pereira-Arenas S, Lechuga-Vieco AV, et al: Screening of effective pharmacological treatments for MELAS syndrome using yeasts, fibroblasts and cybrids models of the disease. Br J Pharmacol 167:1311-1328 (2012).
32.
Gempel K, Topaloglu H, Talim B, Schneiderat P, Schoser BG, et al: The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 130:2037-2044 (2007).
33.
Golbidi S, Ebadi SA, Laher I: Antioxidants in the treatment of diabetes. Curr Diabetes Rev 7:106-125 (2011).
34.
Gold R, Seibel P, Reinelt G, Schindler R, Landwehr P, et al: Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. Eur Neurol 36:191-196 (1996).
35.
Golomb BA, Evans MA, Dimsdale JE, White HL: Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 172:1180-1182 (2012).
36.
Greenberg S, Frishman WH: Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 30:596-608 (1990).
37.
Groneberg DA, Kindermann B, Althammer M, Klapper M, Vormann J, et al: Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int J Biochem Cell Biol 37:1208-1218 (2005).
38.
Haas RH: The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 7(suppl):S136-S145 (2007).
39.
Hadj A, Pepe S, Rosenfeldt F: The clinical application of metabolic therapy for cardiovascular disease. Heart Lung Circ 16(suppl 3):S56-S64 (2007).
40.
Hargreaves IP, Duncan AJ, Heales SJ, Land JM: The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications. Drug Saf 28:659-676 (2005).
41.
Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, et al: Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 62:621-626 (2005).
42.
Hathcock JN, Shao A: Risk assessment for coenzyme Q10 (Ubiquinone). Regul Toxicol Pharmacol 45:282-288 (2006).
43.
Henchcliffe C, Beal MF: Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4:600-609 (2008).
44.
Hernández-Ojeda J, Cardona-Muñoz EG, Román-Pintos LM, Troyo-Sanromán R, Ortiz-Lazareno PC, et al: The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J Diabetes Complications 26:352-358 (2012).
45.
Hershey AD, Powers SW, Vockell AL, Lecates SL, Ellinor PL, et al: Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 47:73-80 (2007).
46.
Hidaka T, Fujii K, Funahashi I, Fukutomi N, Hosoe K: Safety assessment of coenzyme Q10 (CoQ10). Biofactors 32:199-208 (2008).
47.
Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD: Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 56:1137-1142 (2002).
48.
Horstink MW, van Engelen BG: The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Arch Neurol 60:1170-1172 (2003).
49.
Hosoe K, Kitano M, Kishida H, Kubo H, Fujii K, Kitahara M: Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol 47:19-28 (2007).
50.
Jolliet P, Simon N, Barré J, Pons JY, Boukef M, et al: Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 36:506-509 (1998).
51.
Kerr DS: Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 99:246-255 (2010).
52.
Kishi T, Watanabe T, Folkers K: Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. Res Commun Chem Pathol Pharmacol 17:157-164 (1977).
53.
Kwong LK, Kamzalov S, Rebrin I, Bayne AC, Jana CK, et al: Effects of coenzyme Q10 administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic Biol Med 33:627-638 (2002).
54.
Langsjoen H, Langsjoen P, Willis R, Folkers K: Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med 15(suppl):S165-S175 (1994a).
55.
Langsjoen P, Willis R, Folkers K: Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 15 Suppl:S265-272 (1994b).
56.
Lee BJ, Huang YC, Chen SJ, Lin PT: Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 28:250-255 (2012a).
57.
Lee BJ, Huang YC, Chen SJ, Lin PT: Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 28:767-772 (2012b).
58.
Lee J, Boo JH, Ryu H: The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start? Adv Drug Deliv Rev 61:1316-1323 (2009).
59.
Littarru GP, Tiano L: Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 37:31-37 (2007).
60.
Littarru GP, Tiano L: Clinical aspects of coenzyme Q10: an update. Nutrition 26:250-254 (2010).
61.
Liu J, Wang L, Zhan SY, Xia Y: Coenzyme Q10 for Parkinson's disease. Cochrane Database Syst Rev CD008150 (2011).
62.
Lockwood K, Moesgaard S, Hanioka T, Folkers K: Apparent partial remission of breast cancer in ‘high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 15(suppl): S231-S240 (1994).
63.
Lönnrot K, Pörsti I, Alho H, Wu X, Hervonen A, Tolvanen JP: Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. Br J Pharmacol 124:1500-1506 (1998).
64.
López-Lluch G, Rodríguez-Aguilera JC, Santos-Ocaña C, Navas P: Is coenzyme Q a key factor in aging? Mech Ageing Dev 131:225-235 (2010).
65.
Lynch DR, Perlman SL, Meier T: A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 67:941-947 (2010).
66.
Lyon W, Van den Brink O, Pepe S, Wowk M, Marasco S, Rosenfeldt FL: Similar therapeutic serum levels attained with emulsified and oil-based preparations of coenzyme Q10. Asia Pac J Clin Nutr 10:212-215 (2001).
67.
Mancini A, Balercia G: Coenzyme Q10 in male infertility: physiopathology and therapy. Biofactors 37:374-380 (2011).
68.
Mancini A, De Marinis L, Oradei A, Hallgass ME, Conte G, et al: Coenzyme Q10 concentrations in normal and pathological human seminal fluid. J Androl 15:591-594 (1994).
69.
Mancini A, De Marinis L, Littarru GP, Balercia G: An update of Coenzyme Q10 implications in male infertility: biochemical and therapeutic aspects. Biofactors 25:165-174 (2005).
70.
Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G: Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets 11:111-121 (2010).
71.
Mas E, Mori TA: Coenzyme Q10 and statin myalgia: what is the evidence? Curr Atheroscler Rep 12:407-413 (2010).
72.
Miles MV: The uptake and distribution of coenzyme Q10. Mitochondrion 7(suppl):S72-S77 (2007).
73.
Miles MV, Patterson BJ, Schapiro MB, Hickey FJ, Chalfonte-Evans M, et al: Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial. Pediatr Neurol 35:30-37 (2006).
74.
Miyake Y, Shouzu A, Nishikawa M, Yonemoto T, Shimizu H, et al: Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung 49:324-329 (1999).
75.
Mohr D, Bowry VW, Stocker R: Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 1126:247-254 (1992).
76.
Moreno-Fernández AM, Cordero MD, Garrido-Maraver J, Alcocer-Gómez E, Casas-Barquero N, et al: Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. J Psychiatr Res 46:341-345 (2012).
77.
Mortensen SA: Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of ‘Q-symbio' - a multinational trial. Biofactors 18:79-89 (2003).
78.
Mortensen SA, Leth A, Agner E, Rohde M: Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 18(suppl):S137-S144 (1997).
79.
Müller T, Büttne T, Gholipour AF, Kuhn W: Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 341:201-204 (2003).
80.
Naia L, Ribeiro MJ, Rego AC: Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q. Rev Neurosci 23:13-28 (2011).
81.
Naini A, Lewis VJ, Hirano M, DiMauro S: Primary coenzyme Q10 deficiency and the brain. Biofactors 18:145-152 (2003).
82.
Noia G, Littarru GP, De Santis M, Oradei A, Mactromarino C, et al: Coenzyme Q10 in pregnancy. Fetal Diagn Ther 11:264-270 (1996).
83.
Ochiai A, Itagaki S, Kurokawa T, Kobayashi M, Hirano T, Iseki K: Improvement in intestinal coenzyme Q10 absorption by food intake. Yakugaku Zasshi 127:1251-1254 (2007).
84.
Ogasahara S, Engel AG, Frens D, Mack D: Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA 86:2379-2382 (1989).
85.
Palamakula A, Soliman M, Khan MM: Regional permeability of coenzyme Q10 in isolated rat gastrointestinal tracts. Pharmazie 60:212-214 (2005).
86.
Palan PR, Mikhail MS, Shaban DW, Romney SL: Plasma concentrations of coenzyme Q10 and tocopherols in cervical intraepithelial neoplasia and cervical cancer. Eur J Cancer Prev 12:321-326 (2003).
87.
Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL: Coenzyme Q10 in cardiovascular disease. Mitochondrion 7(suppl): S154-S167 (2007).
88.
Playford DA, Watts GF, Croft KD, Burke V: Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 168:169-179 (2003).
89.
Prakash S, Sunitha J, Hans M: Role of coenzyme Q10 as an antioxidant and bioenergizer in periodontal diseases. Indian J Pharmacol 42:334-337 (2010).
90.
Quinzii CM, Hirano M: Primary and secondary CoQ10 deficiencies in humans. Biofactors 37:361-365 (2011).
91.
Quinzii CM, Kattah AG, Naini A, Akman HO, Mootha VK, et al: Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. Neurology 64:539-541 (2005).
92.
Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, et al: A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 78:345-349 (2006).
93.
Quinzii CM, DiMauro S, Hirano M: Human coenzyme Q10 deficiency. Neurochem Res 32:723-727 (2007).
94.
Rodríguez-Hernández A, Cordero MD, Salviati L, Artuch R, Pineda M, et al: Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. Autophagy 5:19-32 (2009).
95.
Roffe L, Schmidt K, Ernst E: Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol 22:4418-4424 (2004).
96.
Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, et al: Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 21:297-306 (2007).
97.
Rötig A, Appelkvist EL, Geromel V, Chretien D, Kadhom N, et al: Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 356:391-395 (2000).
98.
Rötig A, Mollet J, Rio M, Munnich A: Infantile and pediatric quinone deficiency diseases. Mitochondrion 7(suppl):S112-S121 (2007).
99.
Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, et al: Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22:137-141 (2002).
100.
Rusciani L, Proietti I, Rusciani A, Paradisi A, Sbordoni G, et al: Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 54:234-241 (2006).
101.
Sacconi S, Trevisson E, Salviati L, Aymé S, Rigal O, et al: Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 20:44-48 (2010).
102.
Safarinejad MR: The effect of coenzyme Q10 supplementation on partner pregnancy rate in infertile men with idiopathic oligoasthenoteratozoospermia: an open-label prospective study. Int Urol Nephrol 44:689-700 (2012).
103.
Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, et al: Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 65:606-608 (2005).
104.
Sander S, Coleman CI, Patel AA, Kluger J, White CM: The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 12:464-472 (2006).
105.
Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, et al: Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64:713-715 (2005).
106.
Santos-González M, Gómez Díaz C, Navas P, Villalba JM: Modifications of plasma proteome in long-lived rats fed on a coenzyme Q10-supplemented diet. Exp Gerontol 42:798-806 (2007).
107.
Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F: Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 32:179-183 (2008).
108.
Serebruany VL, Ordonez JV, Herzog WR, Rohde M, Mortensen SA, et al: Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharmacol 29:16-22 (1997).
109.
Shults CW, Haas RH, Passov D, Beal MF: Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42:261-264 (1997).
110.
Shults CW, Beal MF, Fontaine D, Nakano K, Haas RH: Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 50:793-795 (1998).
111.
Shults CW, Haas RH, Beal MF: A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors 9:267-272 (1999).
112.
Shults CW, Flint Beal M, Song D, Fontaine D: Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 188:491-494 (2004).
113.
Singh U, Devaraj S, Jialal I: Coenzyme Q10 supplementation and heart failure. Nutr Rev 65:286-293 (2007).
114.
Sohal RS, Forster MJ: Coenzyme Q, oxidative stress and aging. Mitochondrion 7(suppl): S103-S111 (2007).
115.
Sohmiya M, Tanaka M, Tak NW, Yanagisawa M, Tanino Y, et al: Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci 223:161-166 (2004).
116.
Stack EC, Matson WR, Ferrante RJ: Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann N Y Acad Sci 1147:79-92 (2008).
117.
Teran E, Hernandez I, Nieto B, Tavara R, Ocampo JE, Calle A: Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia. Int J Gynaecol Obstet 105:43-45 (2009).
118.
Tiano L, Busciglio J: Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q10? Biofactors 37:386-392 (2011).
119.
Tiano L, Carnevali P, Padella L, Santoro L, Principi F, et al: Effect of Coenzyme Q10 in mitigating oxidative DNA damage in Down syndrome patients, a double blind randomized controlled trial. Neurobiol Aging 32:2103-2105 (2011).
120.
Villalba JM, Parrado C, Santos-González M, Alcain FJ: Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 19:535-554 (2010).
121.
Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF: Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis 14:225-234 (2008).
122.
Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V: Coenzyme Q10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 45:420-426 (2002).
123.
Weber C, Bysted A, Holmer G: Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects. Nutr Res 17:941-945 (1997).
124.
Weis M, Mortensen SA, Rassing MR, Møller-Sonnergaard J, Poulsen G, Rasmussen SN: Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 15(suppl):S273-S280 (1994).
125.
Witting PK, Pettersson K, Letters J, Stocker R: Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice. Free Radic Biol Med 29:295-305 (2000).
126.
Wyman M, Leonard M, Morledge T: Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? Cleve Clin J Med 77:435-442 (2010).
127.
Zhang Y, Aberg F, Appelkvist EL, Dallner G, Ernster L: Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr 125:446-453 (1995).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.